CN109045059A - 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 - Google Patents
一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN109045059A CN109045059A CN201810862523.5A CN201810862523A CN109045059A CN 109045059 A CN109045059 A CN 109045059A CN 201810862523 A CN201810862523 A CN 201810862523A CN 109045059 A CN109045059 A CN 109045059A
- Authority
- CN
- China
- Prior art keywords
- parts
- aging
- energy
- male
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000000463 material Substances 0.000 claims abstract description 43
- 229930182470 glycoside Natural products 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 150000002338 glycosides Chemical group 0.000 claims abstract description 24
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011570 nicotinamide Substances 0.000 claims abstract description 11
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 11
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 11
- 210000004185 liver Anatomy 0.000 claims abstract description 9
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims abstract description 9
- 229960001661 ursodiol Drugs 0.000 claims abstract description 9
- 239000000047 product Substances 0.000 claims description 38
- 230000036541 health Effects 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 14
- 210000003734 kidney Anatomy 0.000 claims description 13
- 235000019441 ethanol Nutrition 0.000 claims description 12
- 239000000341 volatile oil Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 210000004907 gland Anatomy 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 229940107200 chondroitin sulfates Drugs 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 240000006108 Allium ampeloprasum Species 0.000 claims description 5
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 5
- 241000207901 Cuscuta Species 0.000 claims description 5
- 241001533104 Tribulus terrestris Species 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 235000004879 dioscorea Nutrition 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000004513 sizing Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 6
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 230000032683 aging Effects 0.000 abstract description 4
- 210000002149 gonad Anatomy 0.000 abstract description 4
- 230000036299 sexual function Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 230000003138 coordinated effect Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 11
- 229920001282 polysaccharide Polymers 0.000 description 11
- 239000005017 polysaccharide Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 241000282994 Cervidae Species 0.000 description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 9
- 229950006238 nadide Drugs 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000000857 drug effect Effects 0.000 description 8
- 235000018905 epimedium Nutrition 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 7
- 241000893536 Epimedium Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 239000003163 gonadal steroid hormone Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 244000235659 Rubus idaeus Species 0.000 description 4
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 4
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 4
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- -1 flavone glycosides Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000021013 raspberries Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 2
- 241001016310 Epimedium grandiflorum Species 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- NGMYNFJANBHLKA-SENBMHEBSA-N Icariside II Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O)c(C/C=C(\C)/C)c3O2)cc1 NGMYNFJANBHLKA-SENBMHEBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000007382 Ribose-5-phosphate isomerase Human genes 0.000 description 2
- 108020000772 Ribose-Phosphate Pyrophosphokinase Proteins 0.000 description 2
- 102000000439 Ribose-phosphate pyrophosphokinase Human genes 0.000 description 2
- 229910017435 S2 In Inorganic materials 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 108700040099 Xylose isomerases Proteins 0.000 description 2
- 102100029089 Xylulose kinase Human genes 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NGMYNFJANBHLKA-LVKFHIPRSA-N icariside II Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 NGMYNFJANBHLKA-LVKFHIPRSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108020005610 ribose 5-phosphate isomerase Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 108091022915 xylulokinase Proteins 0.000 description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000008361 herbal raw material Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000010630 lipid peroxidation (MDA) assay Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种抗衰老、提高男性精力的组合物，所述组合物包括原料和辅料，所述原料以重量份计，包括1‑15份烟酰胺单核苷酸、1‑10份原人参二醇、1‑9份淫羊藿次级苷I、2‑8份宝藿苷I、3‑7份脱氢表雄酮和2‑10份熊去氧胆酸，该组合物组方合理、配伍得当，组合物中，烟酰胺单核苷酸(NMN)、淫羊藿次级苷I、宝藿苷I、原人参二醇四者共为君药，可全面调节性腺轴、补肾阳、补肝，长期服用可延缓性腺轴衰老周期，提高性功能，各组分件相互协调、协同作用，营养全面，具有很好的适口性，特别适合男性服用，从而缓解男性衰老综合征的症状、提高男性精力。还提供了含有该组合物的制剂及制备工艺，制备方法简单，条件温和，适宜于工业化批量生产。
Description
技术领域
本发明属于保健产品生产技术领域，涉及一种男性保健产品，具体地说涉及一种抗衰老、提高男性精力的组合物、制剂及制剂的制备方法与应用。
背景技术
男女两性由于体质的不同，衰老程度也有差异，因而防治的方法也不相同，一般而言，男性到了五十岁以后雄性激素的机能会逐渐衰退，特别是睾固酮的分泌会逐渐减少，由于这种体内激素分泌的变化，产生了一定身心障碍，临床表现为精神心理症状，如神经过敏、情绪不稳、易激动、急躁、爱发脾气、倦怠，常有压抑感，记忆力、思维能力和注意力减退，睡眠减少、兴趣减退、情绪低沉、反应慢等，并常伴有不安、恐惧、孤独感、缺乏自信心、易纠缠琐事等。
为解决上述问题，目前市面上已涌现出大量良莠不齐的男性保健品，但是常见的保健品都是以中草药原料为基础组分形成的中药制剂制成药物，其中的具体有效成分尚不明朗，且每种原料都未进行原料药的提纯，保健品中有效成分含量低、效果很差，长期服用这些中药保健品还易对身体有毒副作用，另外，中药组合物还存在造价高、口感风味苦、制备方法复杂、原料成本高等问题。
烟酰胺腺嘌呤二核苷酸(NADH)是一种转递质子(更准确来说是氢离子)的辅酶，它出现在细胞很多代谢反应中。烟酰胺腺嘌呤二核苷酸包括氧化形式的烟酰胺腺嘌呤二核苷酸(oxidized nicotinamide adenine dinucleotide，缩写成NAD,也称氧化型辅酶I)。NMN(烟酰胺单核苷酸)是NAD的前体，是一种基本的氧化还原辅酶，不论是在呼吸作用还是光合作用过程，都起着核心枢纽作用，NMN不能直接为分子态氧所氧化，但能通过NMN脱氢酶的作用进行脱氢变成NAD。在呼吸链中，通过这种作用，可使黄素、醌、细胞色素等逐步被还原，最后氧被还原成水。这种以NAD为媒介的底物被O2所氧化的途径，是好氧生物的主要有机物的氧化途径。目前,工业界、医药界或作为生化试剂使用的还烟酰胺单核苷酸(NMN)基本上是通过酵母菌发酵或体外酶催化制备，其应用领域和具体的药代动力学在生物医药领域也处于一个前期的摸索期。目前尚无产品将NMN应用于男性保健领域，以提供一种安全、无毒副作用且高效的男性保健品。
发明内容
为此，本发明所要解决的技术问题在于现男性保健品存在有药效差、对身体有毒副作用、有效成分含量低、成本高、口味不佳、制备方法复杂，从而提出一种效果好、对人体无毒副作用、有效成分含量高、成本低廉、口感丰富、制备工艺简单的抗衰、提高男性精力的组合物、制剂及制剂的制备方法与应用。
为解决上述技术问题，本发明的技术方案为：
本发明提供一种抗衰老、提高男性精力的组合物，其特征在于，所述组合物包括原料和辅料，所述原料以重量份计，包括1-15份烟酰胺单核苷酸、1-10份原人参二醇、1-9份淫羊藿次级苷I、2-8份宝藿苷I、3-7份脱氢表雄酮和2-10份熊去氧胆酸。
作为优选，所述辅料以重量份计，包括2-7份硫酸软骨素和3-8份s-腺蛋氨酸。
作为优选，所述辅料以重量份计，还包括2-3份维生素E、1-3份锌、2-6份维生素B、1-5份山药、2-7份蒺藜、1-3份覆盆子、2-5份菟丝子和2-6份韭菜籽。
本发明还提供一种抗衰老、提高男性精力的制剂，其包括所述的组合物。
本发明还提供一种制备所述抗衰老、提高男性精力制剂的方法，其包括如下步骤：
S1、将原料与辅料分别过50-80目筛，使颗粒粒度均匀；
S2、按照比例将原料、辅料和水在25-40℃下充分搅拌均匀，得到原、辅料的混合物；
S3、将步骤S2得到的混合物升温至50℃后搅拌1h，即得抗衰老、提高男性精力的水剂。
本发明还提供了一种制备所述抗衰老、提高男性精力制剂的方法，其包括如下步骤：
S1、将干燥的主料和辅料各组分过60目筛，并按比例称重混合；
S2、将步骤S1得到的混合物烘干后进行整粒和压片处理，得到抗衰老、提高男性精力的片剂。
本发明还提供了一种制备所述抗衰老、提高男性精力制剂的方法，其包括如下步骤：
S1、将主料和辅料各组分过60目筛，并按比例称重混合；
S2、将步骤S1得到的混合物充填于软胶囊体中，并经过压丸、定型干燥、洗丸、晾丸、捡丸的步骤，得到抗衰老、提高男性精力的软胶囊。
本发明还提供了一种制备所述抗衰老、提高男性精力制剂的方法，其包括如下步骤：
S1、将辅料组分粉碎为颗粒，向颗粒中加入乙醇并加热回流提取2h，乙醇的添加量为组分颗粒质量的5倍，第一次过滤处理，得到药渣和药液，将药渣与3倍量的乙醇加热回流提取1h，第二次过滤处理，将第一次、第二次过滤得到的药液混合，并减压浓缩制得相对密度为1.35-1.4的稠膏备用；
S2、将步骤S1得到的稠膏加7倍量的水，加热回流提取4h，得到挥发油、药渣和药液的混合物，分取所述挥发油，并将药渣和药液过滤分离，得到上清液和固体药渣；
S3、将主料与步骤S2得到的挥发油和药渣混合，加18倍量的水煎煮提取2h，过滤得到滤液和滤渣，将滤液离心分离，得到第一上清液；将滤渣加12倍量的水煎煮提取1h，过滤得到滤液和滤渣，将滤液离心分离，得到第二上清液；将第一上清液、第二上清液与步骤S2中的上清液混合，减压浓缩制得相对密度为1.35-1.4的稠膏备用；
S4、将糊精、微粉硅胶混匀并与步骤S3制得的稠膏共同搅拌均匀，将得到的混合物干燥并粉碎后，加入糊精，喷入步骤S2得到的挥发油后过筛、混匀并装入胶囊壳，得到抗衰老、提高男性精力的胶囊。
作为优选，所述乙醇的体积浓度为70％。
本发明还提供了一种所述的抗衰老、提高男性精力组合物在滋肝养肾保健品、提高免疫力保健品、延缓衰老保健品、促进疲劳恢复保健品中的应用。
本发明的上述技术方案相比现有技术具有以下优点：
(1)本发明所述的抗衰老、提高男性精力的组合物，所述组合物包括原料和辅料，所述原料以重量份计，包括1-15份烟酰胺单核苷酸、1-10份原人参二醇、1-9份淫羊藿次级苷I、2-8份宝藿苷I、3-7份脱氢表雄酮和2-10份熊去氧胆酸，该组合物组方合理、配伍得当，组合物中，烟酰胺单核苷酸(NMN)、淫羊藿次级苷I、宝藿苷I、原人参二醇四者共为君药，可全面调节性腺轴、补肾阳、补肝，长期服用可延缓性腺轴衰老周期，提高性功能，辅料中，硫酸软骨素具有活脉通气的作用，可达到补气血、减少体内钙流失、改善骨质的功效，可增强下丘脑-垂体-性腺轴的功能，s-腺蛋氨酸具有疏通经络的作用，可使硫酸软骨素精微及充足之气血得以输送于肾，从而滋肾坚阴，先天至精得以濡养，熊去氧胆酸作为使药，可调和诸药。所述组合物所选原料配伍相宜，复合中医药和现代医药理论，吸收效果好，无不良及毒副作用，共具填精固肾、补气通脉敛汗、平肝安神的功效，各组分件相互协调、协同作用，营养全面，具有很好的适口性，特别适合男性服用，从而缓解男性衰老综合征的症状、提高男性精力。
(2)本发明所述的抗衰老、提高男性精力的组合物，辅料以重量份计，包括2-7份硫酸软骨素和3-8份s-腺蛋氨酸。其中硫酸软骨素具有活脉通气、补充气血的作用，益于活化筋骨，s-腺苷蛋氨酸有疏通经络的作用，使得硫酸软骨素精微及充足之气血得以输送于肾，从而滋肾坚阴，进一步改善了男性衰老综合征。
(3)本发明所述的抗衰老、提高男性精力的制剂，为集“激活性腺、滋养睾丸、血液动力”三大功效于一身的纯植物制剂，服用简单方便，无毒无害，安全有效、由内而外的从根本上预防、治疗和改善疲劳症和男性男性综合征，减轻了给男人带来的不安和痛苦。该发明以中药成分为主要原料，以治疗为主要目的。
(4)本发明所述的制备抗衰老、提高男性精力的制剂的方法，其工艺步骤简单、条件温和，适宜于工业化批量生产。
具体实施方式
实施例1
本实施例提供一种抗衰老、提高男性精力的组合物，所述组合物包括原料和辅料，其中，所述原料以重量份计，包括1份烟酰胺单核苷酸(NMN)、1份原人参二醇(PPD)、1份淫羊藿次级苷I、2份宝藿苷I、3份脱氢表雄酮(DHEA)和2份熊去氧胆酸，所述辅料以重量份计，包括2份硫酸软骨素和3份s-腺蛋氨酸。
其中，NMN采用如下工艺制备：以烟酰胺、ATP和木糖为原料，在烟酰胺磷酸核糖转移酶、核糖磷酸焦磷酸激酶、核糖-5-磷酸异构酶、核酮糖-3-磷酸异构酶、木酮糖激酶以及木糖异构酶的催化作用下发生反应，制得烟酰胺单核苷酸。具体包括如下步骤：
(1)向反应釜中加入底物溶液，所述底物溶液含30mM的ATP、30mM的木糖、20mM的MgCl2、10mM的KC1以及100mM的Tris-HCl缓冲液，调pH至7.5-8.0。然后加入以下催化用酶：核糖磷酸焦磷酸激酶6g/L底物溶液，核糖-5-磷酸异构酶10g/L底物溶液，核酮糖-3-磷酸异构酶l lg/L底物溶液，木酮糖激酶10g/L底物溶液，木糖异构酶10g/L底物溶液。搅拌均匀后进行反应，反应过程中持续搅拌(搅拌速度50rp m)，控制反应温度为35℃，维持pH值为7.5-8.0。
(2)待上述反应进行4h后，分离出反应液，并将反应液送入另一反应釜中，再向反应液中加入60mM的烟酰胺、30mM的ZnCl2、100mM的Tris-HCl缓冲液以及烟酰胺磷酸核糖转移酶15g/L底物溶液，搅拌均匀后继续反应，反应过程中持续搅拌(搅拌速度50rpm)，控制反应温度为35℃，维持pH值为7.5-8.0，再反应4h后即得烟酰胺单核苷酸粗产品溶液含NMN12mM)，再经过滤、纯化、干燥后即得烟酰胺单核苷酸成品。
所述宝藿苷I通过如下步骤提取：以淫羊藿苷为原料，直接采用β-葡萄糖苷酶酶解淫羊藿苷制备宝藿苷Ⅰ，切断淫羊藿苷C-7位的β-D-葡萄糖，制备高纯度的宝藿苷Ⅰ。研究表明，淫羊藿黄酮苷在肠道的吸收较差，由于人体肠道存在的水解酶(肠道黏膜酶和肠道菌酶)会因人种、年龄、疾病而有所差异，因此会影响淫羊藿黄酮苷的水解进而影响其吸收和疗效的发挥。水解是淫羊藿黄酮苷生物转化的起始步骤，去糖基化使得糖苷易于在肠道扩散和吸收。因此口服淫羊藿黄酮，主要以肠道代谢产物(次级苷或苷元)的形式被吸收而发挥疗效。本发明摒弃了传统的直接采用淫羊藿作为原料药的做法，而是提取了有效成分宝藿苷Ⅰ和淫羊藿苷元，这样做使得抗骨质疏松，增加男性活力等生物活性更强。体外选择高效安全的淫羊藿黄酮苷水解酶，将其对淫羊藿总黄酮甘水解至苷元，可以增强淫羊藿总黄酮的生物利用度，是促进淫羊藿总黄酮口服吸收，提高药效。传统的转化方法一般为化学酸解或碱解，从淫羊藿苷制备宝藿苷，但工艺控制难度大，降解的产物不易控制，副产物多，产品收率低，更重要的的环保因素。采用酶技术生物转化，反应条件温和，专一性强，产品收率高，去糖基化，增加生物利用度。
上述组合物中，PPD来源于人参皂苷，现代药理学研究表明，PPD所带的糖基的种类与数量与其生理活性密切相关，糖基越多活性越低。在人口服人参皂苷以后，多糖基的皂苷需要经过肠道微生物、唾液酶系、肠道酶、胃液的共同作用，转化为另一种结构再起药效。这正是中草药天然成分和化学药的不同之处，化学药口服后直接吸收起药效；中草药天然成分多为前体药物，本身无药效或药效较低，只有在体内转化后才能发挥药效。例如天然的三醇类的多糖基人参皂苷Re、Rg1、Rf难以穿透细胞膜，吸收率低、药理活性低，还有引起上火和流鼻血等副作用。如果将Re、Rg1、Rf等转化成F1、Rh1、Rg2及苷元不仅能大大提高吸收率，还能大幅度提高药效、并降低毒副作用。
本实施例还提供了一种抗衰老、提高男性精力的水剂，所述水剂包括上述组合物，所述水剂通过如下步骤制备：
S1、将原料与辅料分别过30-80目筛，本实施例中，采用50目筛，使颗粒粒度均匀。
S2、按照比例将原料、辅料和水在25-40℃下充分搅拌均匀，所述水与原、辅料总质量的质量比为3:1。
S3、将步骤S2得到的混合物升温至50℃后搅拌1h，即得抗衰老、提高男性精力保健水剂。
所述男性保健水剂可作为滋肝养肾保健品、提高免疫力保健品、延缓衰老保健品、促进疲劳恢复保健品应用。
实施例2
本实施例提供一种抗衰老、提高男性精力的组合物，所述组合物包括原料和辅料，其中，所述原料以重量份计，包括15份烟酰胺单核苷酸(NMN)、10份原人参二醇(PPD)、9份淫羊藿次级苷I、8份宝藿苷I、7份脱氢表雄酮(DHEA)和10份熊去氧胆酸，所述辅料以重量份计，包括7份硫酸软骨素和8份s-腺蛋氨酸，所述辅料还以重量份计，包括2份维生素E、1份锌、2份维生素B、1份山药、2份蒺藜、1份覆盆子、2份菟丝子和2份韭菜籽。
本实施例还提供一种抗衰老、提高男性精力的片剂，所述片剂通过如下步骤制备：
S1、将干燥的主料和辅料各组分过60目筛，并按比例称重混合；
S2、将步骤S1得到的混合物在制粒机中进行制粒，烘干后通过常规工艺进行整粒，并放入压片机进行压片处理，得到抗衰老、提高男性精力的片剂，所述片剂的理论片重为500mg。
所述抗衰老、提高男性精力的片剂可作为滋肝养肾保健品、提高免疫力保健品、延缓衰老保健品、促进疲劳恢复保健品应用。
实施例3
本实施例提供一种抗衰老、提高男性精力的组合物，所述组合物包括原料和辅料，其中，所述原料以重量份计，包括8份烟酰胺单核苷酸(NMN)、5份原人参二醇(PPD)、5份淫羊藿次级苷I、6份宝藿苷I、5份脱氢表雄酮(DHEA)和6份熊去氧胆酸，所述辅料以重量份计，包括5份硫酸软骨素和6份s-腺蛋氨酸，所述辅料还以重量份计，包括3份维生素E、3份锌、6份维生素B、5份山药、7份蒺藜、3份覆盆子、5份菟丝子和6份韭菜籽。
本实施例还提供一种抗衰老、提高男性精力的软胶囊，所述软胶囊通过如下步骤制备：
S1、将主料和辅料各组分过60目筛，并按比例称重混合；
S2、将步骤S1得到的混合物充填于软胶囊体中，并经过压丸、定型干燥、洗丸、晾丸、捡丸的步骤，得到抗衰老、提高男性精力的软胶囊。所述软胶囊体以常规工艺制备：将甘油和水加入溶胶罐中，随后分别加入明胶和相关辅料，搅拌、真空脱气，制得软胶囊体。
所述抗衰老、提高男性精力的软胶囊可作为滋肝养肾保健品、提高免疫力保健品、延缓衰老保健品、促进疲劳恢复保健品应用。
实施例4
本实施例提供一种抗衰老、提高男性精力的组合物，所述组合物包括原料和辅料，其中，所述原料以重量份计，包括6份烟酰胺单核苷酸(NMN)、7份原人参二醇(PPD)、7份淫羊藿次级苷I、4份宝藿苷I、6份脱氢表雄酮(DHEA)和8份熊去氧胆酸，所述辅料以重量份计，包括4份硫酸软骨素和5份s-腺蛋氨酸，所述辅料还以重量份计，包括2.5份维生素E、2份锌、4份维生素B、3份山药、5份蒺藜、2份覆盆子、4份菟丝子和4份韭菜籽。
本实施例还提供一种抗衰老、提高男性精力的保健胶囊，所述抗衰老、提高男性精力的保健胶囊通过如下步骤制备：
S1、将辅料组分粉碎为粗颗粒，所述粗颗粒的粒径为50μm，向颗粒中加体积浓度70％的乙醇加热回流提取2h，乙醇的添加量为辅料组分颗粒质量的5倍，然后第一次过滤处理，得到药渣和药液，将药渣与3倍量的乙醇加热回流提取1h，第二次过滤处理，将第一次、第二次过滤得到的药液混合，并减压浓缩制得相对密度为1.35-1.4的稠膏备用。
S2、将步骤S1得到的稠膏加7倍量的水，加热回流提取4h，得到挥发油、药渣和药液的混合物，分取所述挥发油，并将药渣和药液过滤分离，得到上清液和固体药渣。
S3、将主料与步骤S2得到的挥发油和药渣混合，加18倍量的水煎煮提取2h，过滤得到滤液和滤渣，将滤液离心分离，得到第一上清液；将滤渣加12倍量的水煎煮提取1h，过滤得到滤液和滤渣，将滤液离心分离，得到第二上清液；将第一上清液、第二上清液与步骤S2中的上清液混合，减压浓缩制得相对密度为1.35-1.4的稠膏备用。
S4、将糊精、微粉硅胶混匀并与步骤S3制得的稠膏共同搅拌均匀，将得到的混合物干燥并粉碎后，加入糊精，喷入步骤S2得到的挥发油后过筛、混匀并装入胶囊壳，得到抗衰老、提高男性精力胶囊。
所述抗衰老、提高男性精力保健胶囊可作为滋肝养肾保健品、提高免疫力保健品、延缓衰老保健品、促进疲劳恢复保健品应用。
实验例
1、安全性验证
将实施例3所述的男性保健组合物进行安全性验证，采用本领域常规验证方法进行验证，试验结果如下：
(1)急性毒性实验表明：根据急性毒性剂量分级标准，属实际无毒性级；
(2)骨髓细胞微核试验、精子畸形试验、Ames试验结果为阴性；
(3)30天喂养试验：实验动物生长情况良好，血液学检查，生化学检查，主要脏体比及组织学检材料、动物及其它查结果与对照组相比，均未见异常，证明实施例所述的组合物安全无毒。
2、动物试验
选取雄性Wistar大鼠63只，体重(200±20)g，由兰州大学医学实验动物中心提供，适应性养殖数天，大鼠按12h白昼的节律调节光照，保持适宜的温度和相对湿度。实验动物随机分为正常组、阳性对照组、3个不同剂量的实验组以及0.1g/(kg d)(每公斤大鼠所用枸杞多糖的量)枸杞多糖对照组和0.1g/(kg d)(每公斤大鼠所用鹿血的量)鹿血对照组，每组9只。3个剂量组分别给予0.05、0.1和0.2g/(kg d)(每公斤大鼠所用枸杞多糖、鹿血组合物的多糖和鹿血含量之和)剂量实施例2所述的组合物，用生理盐水稀释，按照1mL/(100g)灌胃。2个对照组每日灌胃等体积生理盐水，连续14d。除正常对照组外，其余各组采用Michiharu Miura等方法(Stroke,2001,32(5):1201-1207)，温水浴造模。于造模24h后，称体重，股动脉放血，处死动物。
(1)股动脉放血，取血清，放射免疫法测定血清睾酮(T)、垂体间质细胞刺激素(LH)和垂体精子生成素(FSH)含量。
实验数据采用SPSS软件做方差分析及组间比较。结果表明，低剂量组(0.05g/(kgd))能明显提高大鼠血清T、LSH、FSH性激素水平，与阳性对照组比较差异有高度显著性(P<0.01)；其它实验组大鼠血清性激素水平均有一定的提高。枸杞多糖和鹿血组相对于阳性对照组，大鼠血清性激素水平均有一定提高，但不及组合物各剂量组。说明枸杞多糖和鹿血的结合，可以更好地保护大鼠生殖系统，促进睾丸生殖细胞的正常发育。
(2)睾丸组织SOD活力测定和MDA含量测定：取大鼠一侧睾丸称重，加生理盐水，冰浴下制成质量浓度为10％的组织匀浆，离心后取上清液迅速冷冻保存，测定睾丸组织中SOD水平和MDA含量，结果如表1所示。
表1
| 组别 | 动物数量(只) | SOD(NU mg/prot) | MDA(NU mg/prot) |
| 正常对照组 | 9 | 332.17±24.38** | 1.05±0.45** |
| 阳性对照组 | 9 | 254.31±12.34 | 3.23±1.55 |
| 低剂量0.05g(kg d) | 9 | 386.75±26.98** | 5.22±0.14** |
| 中剂量0.1g(kg d) | 9 | 282.89±14.59** | 3.67±1.05** |
| 高剂量0.2g(kg d) | 9 | 271.52±32.57** | 1.57±0.85** |
| 枸杞多糖0.1g(kg d) | 9 | 246.26±26.43 | 1.86±0.47 |
| 鹿血0.1g(kg d) | 9 | 253.92±27.55 | 1.39±0.43 |
上述结果表明，本发明实施例所述的组合物、枸杞多糖、鹿血均能提高大鼠睾丸组织中SOD活性，降低MDA含量，增强大鼠抗氧化能力，并且本发明实施例所述的组合物比枸杞多糖和鹿血组的活性更强，且低剂量组能明显提高大鼠血清T、LSH、FSH性激素水平，与阳性对照组比较差异有高度显著性(P<0.01)。因此，本发明组合物具有男性保健的作用。
3、临床实验例
a、病例1
某男，43岁；主诉：工作压力大、易疲劳、性功能低下。
查体：舌质红、少苔、脉弦细数、精神差、属肾阳虚型性功能障碍。
治疗：服用本发明实施例2所述的制剂，每日1次，每次2片。
效果：服用一个疗程显效，服用两个疗程后，精力旺盛、性功能强盛。
b、病例2
某男，50岁；主诉：前列腺炎、性生活不协调、早泄、精少。
查体：脉象沉细、无力、舌淡红、苔白。属：肾阴不足、肾阳虚引起的性功能障碍，。
治疗：服用本发明实施例1所述制剂，每日1次，每次50ml。
效果：服用一个疗程有晨勃，两个疗程后性功能显著提高，一年后跟踪调查，本人精神矍铄，精力十足，夫妻生活和谐。
c、病例3
某男，43岁；主诉：甚感精力不足、易疲劳、乏力、失眠，婚后5年不生育，就医，精少、成活率低，医治无显著效果。
查体：脉细软无力，舌色淡、眼无神，属阴虚型抗疲劳能力低下，营养不良，造精能力低下。
治疗：服用本发明实施例3所述制剂，每日1次，每次2粒。
效果：服用一个疗程后，抗疲劳效果显著，其他症状明显改善，精力旺盛。服用两个疗程后，精子量增多，成活率提高30％，坚持服用一年三个月，妻子怀孕。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (10)
1.一种抗衰老、提高男性精力的组合物，其特征在于，所述组合物包括原料和辅料，所述原料以重量份计，包括1-15份烟酰胺单核苷酸、1-10份原人参二醇、1-9份淫羊藿次级苷I、2-8份宝藿苷I、3-7份脱氢表雄酮和2-10份熊去氧胆酸。
2.根据权利要求1所述的抗衰老、提高男性精力的组合物，其特征在于，所述辅料以重量份计，包括2-7份硫酸软骨素和3-8份s-腺蛋氨酸。
3.根据权利要求2所述的抗衰老、提高男性精力的组合物，其特征在于，所述辅料以重量份计，还包括2-3份维生素E、1-3份锌、2-6份维生素B、1-5份山药、2-7份蒺藜、1-3份覆盆子、2-5份菟丝子和2-6份韭菜籽。
4.一种抗衰老、提高男性精力的制剂，其特征在于，包括如权利要求1-3任一项所述的组合物。
5.一种制备如权利要求4所述的抗衰老、提高男性精力制剂的方法，其特征在于，包括如下步骤：
S1、将原料与辅料分别过50-80目筛，使颗粒粒度均匀；
S2、按照比例将原料、辅料和水在25-40℃下充分搅拌均匀，得到原、辅料的混合物；
S3、将步骤S2得到的混合物升温至50℃后搅拌1h，即得抗衰老、提高男性精力的水剂。
6.一种制备如权利要求4所述的抗衰老、提高男性精力制剂的方法，其特征在于，包括如下步骤：
S1、将干燥的主料和辅料各组分过60目筛，并按比例称重混合；
S2、将步骤S1得到的混合物烘干后进行整粒和压片处理，得到抗衰老、提高男性精力的片剂。
7.一种制备如权利要求4所述的抗衰老、提高男性精力制剂的方法，其特征在于，包括如下步骤：
S1、将主料和辅料各组分过60目筛，并按比例称重混合；
S2、将步骤S1得到的混合物充填于软胶囊体中，并经过压丸、定型干燥、洗丸、晾丸、捡丸的步骤，得到抗衰老、提高男性精力的软胶囊。
8.一种制备如权利要求4所述的抗衰老、提高男性精力制剂的方法，其特征在于，包括如下步骤：
S1、将辅料组分粉碎为颗粒，向颗粒中加入乙醇并加热回流提取2h，乙醇的添加量为组分颗粒质量的5倍，第一次过滤处理，得到药渣和药液，将药渣与3倍量的乙醇加热回流提取1h，第二次过滤处理，将第一次、第二次过滤得到的药液混合，并减压浓缩制得相对密度为1.35-1.4的稠膏备用；
S2、将步骤S1得到的稠膏加7倍量的水，加热回流提取4h，得到挥发油、药渣和药液的混合物，分取所述挥发油，并将药渣和药液过滤分离，得到上清液和固体药渣；
S3、将主料与步骤S2得到的挥发油和药渣混合，加18倍量的水煎煮提取2h，过滤得到滤液和滤渣，将滤液离心分离，得到第一上清液；将滤渣加12倍量的水煎煮提取1h，过滤得到滤液和滤渣，将滤液离心分离，得到第二上清液；将第一上清液、第二上清液与步骤S2中的上清液混合，减压浓缩制得相对密度为1.35-1.4的稠膏备用；
S4、将糊精、微粉硅胶混匀并与步骤S3制得的稠膏共同搅拌均匀，将得到的混合物干燥并粉碎后，加入糊精，喷入步骤S2得到的挥发油后过筛、混匀并装入胶囊壳，得到抗衰老、提高男性精力的胶囊。
9.根据权利要求8所述的抗衰老、提高男性精力制剂的方法，其特征在于，所述乙醇的体积浓度为70％。
10.一种如权利要求1-3任一项所述的抗衰老、提高男性精力的组合物在滋肝养肾保健品、提高免疫力保健品、延缓衰老保健品、促进疲劳恢复保健品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810862523.5A CN109045059A (zh) | 2018-08-01 | 2018-08-01 | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810862523.5A CN109045059A (zh) | 2018-08-01 | 2018-08-01 | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109045059A true CN109045059A (zh) | 2018-12-21 |
Family
ID=64832225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810862523.5A Withdrawn CN109045059A (zh) | 2018-08-01 | 2018-08-01 | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109045059A (zh) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674808A (zh) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途 |
| CN110237089A (zh) * | 2019-06-19 | 2019-09-17 | 泓博元生命科技（深圳）有限公司 | Nadh和/或nmn防治男性勃起功能障碍的应用 |
| CN110585268A (zh) * | 2019-09-18 | 2019-12-20 | 广东粤微生物科技有限公司 | 一种提高男性耐力和精力活力的组合物及其制备方法和用途 |
| CN111035649A (zh) * | 2019-11-15 | 2020-04-21 | 臻元国际(香港)有限公司 | 一种nmn+glp复配营养补充剂及其制备方法和应用 |
| CN111603552A (zh) * | 2020-07-02 | 2020-09-01 | 中健智诊(重庆)生物研究院 | 一种抗衰老组合物及其应用 |
| CN112795457A (zh) * | 2021-01-07 | 2021-05-14 | 陈广会 | 一种有机抗衰老饮料及其制备方法 |
| CN113209166A (zh) * | 2021-05-28 | 2021-08-06 | 成都健腾生物技术有限公司 | 一种含烟酰胺单核苷酸的抗衰老中药组合物及其制备方法 |
| WO2021202245A1 (en) * | 2020-04-02 | 2021-10-07 | Egaceutical Corporation | Viral treatment regimens |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1638650A (zh) * | 2001-03-09 | 2005-07-13 | 雀巢制品公司 | 改善与年龄有关的生理缺陷并延长寿命的组合物 |
| CN102178956A (zh) * | 2011-04-21 | 2011-09-14 | 李国玉 | 20S-原人参二醇β-环糊精包合物制备及其医药用途和组合物 |
| CN104187643A (zh) * | 2014-08-16 | 2014-12-10 | 胡安然 | 阳虚体质全营养配方食品 |
| CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
| CN105434576A (zh) * | 2015-11-27 | 2016-03-30 | 天津天狮生物发展有限公司 | 一种具有男性保健功能的组合物及其制备方法 |
| CN107233511A (zh) * | 2017-06-14 | 2017-10-10 | 安徽济人药业有限公司 | 一种疏风解毒胶囊及其制备方法与检测方法及用途 |
| CN107890473A (zh) * | 2017-11-27 | 2018-04-10 | 中国科学院兰州化学物理研究所 | 一种具有缓解疲劳和壮阳功能的组合物 |
-
2018
- 2018-08-01 CN CN201810862523.5A patent/CN109045059A/zh not_active Withdrawn
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1638650A (zh) * | 2001-03-09 | 2005-07-13 | 雀巢制品公司 | 改善与年龄有关的生理缺陷并延长寿命的组合物 |
| CN102178956A (zh) * | 2011-04-21 | 2011-09-14 | 李国玉 | 20S-原人参二醇β-环糊精包合物制备及其医药用途和组合物 |
| CN104187643A (zh) * | 2014-08-16 | 2014-12-10 | 胡安然 | 阳虚体质全营养配方食品 |
| CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
| CN105434576A (zh) * | 2015-11-27 | 2016-03-30 | 天津天狮生物发展有限公司 | 一种具有男性保健功能的组合物及其制备方法 |
| CN107233511A (zh) * | 2017-06-14 | 2017-10-10 | 安徽济人药业有限公司 | 一种疏风解毒胶囊及其制备方法与检测方法及用途 |
| CN107890473A (zh) * | 2017-11-27 | 2018-04-10 | 中国科学院兰州化学物理研究所 | 一种具有缓解疲劳和壮阳功能的组合物 |
Non-Patent Citations (5)
| Title |
|---|
| 夏从龙等: "《大理苍山植物药物志》", 31 March 2016 * |
| 李爱科: "《养好肾年轻20岁》", 31 March 2018 * |
| 詹姆斯•巴克等: "《实用家庭营养治疗处方百科》", 30 September 2000 * |
| 许浩等: "HPLC法测定复方鹿茸酒中尿囊素、山药素I、淫羊藿苷、淫羊藿次苷I和宝藿苷I", 《现代药物与临床》 * |
| 陈其福: "《走出亚健康500个为什么》", 31 December 2006 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674808A (zh) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途 |
| CN110237089A (zh) * | 2019-06-19 | 2019-09-17 | 泓博元生命科技（深圳）有限公司 | Nadh和/或nmn防治男性勃起功能障碍的应用 |
| WO2020253493A1 (zh) * | 2019-06-19 | 2020-12-24 | 泓博元生命科技（深圳）有限公司 | Nadh 和 / 或 nmn 防治男性勃起功能障碍的应用 |
| CN110585268A (zh) * | 2019-09-18 | 2019-12-20 | 广东粤微生物科技有限公司 | 一种提高男性耐力和精力活力的组合物及其制备方法和用途 |
| CN111035649A (zh) * | 2019-11-15 | 2020-04-21 | 臻元国际(香港)有限公司 | 一种nmn+glp复配营养补充剂及其制备方法和应用 |
| CN111035649B (zh) * | 2019-11-15 | 2021-03-19 | 臻元国际(香港)有限公司 | 一种nmn+glp复配营养补充剂及其制备方法和应用 |
| WO2021202245A1 (en) * | 2020-04-02 | 2021-10-07 | Egaceutical Corporation | Viral treatment regimens |
| CN111603552A (zh) * | 2020-07-02 | 2020-09-01 | 中健智诊(重庆)生物研究院 | 一种抗衰老组合物及其应用 |
| CN112795457A (zh) * | 2021-01-07 | 2021-05-14 | 陈广会 | 一种有机抗衰老饮料及其制备方法 |
| CN113209166A (zh) * | 2021-05-28 | 2021-08-06 | 成都健腾生物技术有限公司 | 一种含烟酰胺单核苷酸的抗衰老中药组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109045059A (zh) | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 | |
| CN106606529A (zh) | 一种具有辅助降血糖功效的组合物及其制备方法和应用 | |
| CN106806643A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN102302211A (zh) | 一种保健饮品 | |
| CN104784505A (zh) | 一种辅助降血糖的铁皮石斛保健品及其制备方法 | |
| CN102349608A (zh) | 一种清咽润喉的保健品组合物及其制备方法 | |
| CN109123351A (zh) | 一种具有高血糖人群代餐调节功能的特医食品及制备方法 | |
| CN108651993A (zh) | 一种男性保健组合物、制剂及其制备方法与应用 | |
| CN109350624A (zh) | 含有nmn和dhea的女性保健组合物、制剂及其制备方法与应用 | |
| CN109364171A (zh) | 含有nadh和dhea的卵巢保养组合物、制剂及其制备方法 | |
| CN105640971B (zh) | 未成熟罗汉果提取物中的总皂苷在制备辅助降血糖药物方面的应用 | |
| CN101278949A (zh) | 一种组合物及其制备方法和用途 | |
| CN110693029A (zh) | 一种降血糖桑叶苦瓜功能食品 | |
| CN109588723A (zh) | 一种富硒青稞菌粉及其加工方法 | |
| CN104940241A (zh) | 一种防治妇女更年期综合征的硒虫草复方制剂 | |
| CN109123621A (zh) | 一种可调节机体免疫功能抑制血糖升高的保健食品 | |
| CN115089661A (zh) | 辅助调节内分泌代谢并抗癌防癌的人参组合物的应用 | |
| CN113648347A (zh) | 含莲子外泌体的卵巢保养的组合物及其制备方法 | |
| CN106942561A (zh) | 一种饮料组合物及其制备方法与应用 | |
| CN113413419A (zh) | 含大枣外泌体的卵巢保养的组合物及其制备方法 | |
| CN103933282B (zh) | 一种治疗糖尿病的中药胶囊 | |
| CN104825379A (zh) | 减少黑色素沉积的美白焕肤晚霜及其制备方法 | |
| CN108524850A (zh) | 一种用于增强免疫、防治心脑血管疾病的酒制剂 | |
| CN109123655A (zh) | 一种具有三高人群代餐调节功能的特医食品及制备方法 | |
| CN110101813A (zh) | 一种治疗肾阳虚牡蛎组合物口服液制备方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181221 |